MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Losartan Versus Atenolol for the Treatment of Marfan Syndrome

Phase 2
Completed
Conditions
Marfan Syndrome
Interventions
First Posted Date
2008-01-15
Last Posted Date
2012-07-12
Lead Sponsor
University of British Columbia
Target Recruit Count
17
Registration Number
NCT00593710
Locations
🇨🇦

Children's Heart Centre, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada

An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))

Phase 3
Completed
Conditions
Proteinuria
Interventions
First Posted Date
2007-12-05
Last Posted Date
2024-05-23
Lead Sponsor
Organon and Co
Target Recruit Count
306
Registration Number
NCT00568178

Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Not Applicable
Completed
Conditions
Obese
Type 2 Diabetes
Diabetic Nephropathy
Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers
First Posted Date
2007-11-21
Last Posted Date
2007-11-21
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
80
Registration Number
NCT00561704

PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites

Conditions
Hypertension
Interventions
First Posted Date
2007-11-20
Last Posted Date
2007-11-20
Lead Sponsor
German Heart Institute
Registration Number
NCT00561327
Locations
🇩🇪

German Heart Institute, Berlin, Germany

VA NEPHRON-D: Diabetes iN Nephropathy Study

Phase 3
Terminated
Conditions
Kidney Disease
Nephropathy
Type 2 Diabetes
Interventions
First Posted Date
2007-11-08
Last Posted Date
2015-05-29
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
1448
Registration Number
NCT00555217
Locations
🇺🇸

VA Palo Alto Health Care System, Palo Alto, California, United States

🇵🇷

VA Medical Center, San Juan, San Juan, Puerto Rico

🇺🇸

VA Medical Center, Memphis, Memphis, Tennessee, United States

and more 28 locations

A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)

Phase 3
Completed
Conditions
Hypertension
Metabolic Disorder
Interventions
First Posted Date
2007-10-18
Last Posted Date
2024-05-16
Lead Sponsor
Organon and Co
Target Recruit Count
1738
Registration Number
NCT00546052

Losartan Therapy in Pulmonary Hypertension

Phase 3
Completed
Conditions
Pulmonary Hypertension
Interventions
First Posted Date
2007-08-23
Last Posted Date
2007-08-23
Lead Sponsor
Baskent University
Registration Number
NCT00519870

LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)

Phase 4
Completed
Conditions
Hypertension
Interventions
First Posted Date
2007-07-04
Last Posted Date
2024-05-22
Lead Sponsor
Organon and Co
Target Recruit Count
201
Registration Number
NCT00496834

Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome

Phase 1
Terminated
Conditions
Hermansky-Pudlak Syndrome (HPS)
Pulmonary Fibrosis
Oculocutaneous Albinism
Platelet Storage Pool Deficiency
Metabolic Disease
Interventions
First Posted Date
2007-05-01
Last Posted Date
2013-08-02
Lead Sponsor
National Human Genome Research Institute (NHGRI)
Target Recruit Count
3
Registration Number
NCT00467831
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath